16 September 2026 editorial review · Trial
RESET T1D: rezpegaldesleukin (NKTR-358), a Treg-selective IL-2, in new-onset T1D: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Baseline trial evidence review: M–S
Outcome: Corrected direct item relationships; shared class or background is insufficient.
Registry: NCT07142252. Endpoint reviewed: The area under the stimulated C-peptide curve (AUC) Y_MAUC. (12 Months). Eligibility reviewed: Age 8 Years to 45 Years; diagnosis/stage, prior therapy and key biomarker criteria compared with site summary. Full exclusions remain in the registry. Literature access limit: No usable primary abstract was independently recovered for this record in this pass. Current registry protocol was the main source; detailed sponsor or conference data remain dependent on the cited source and were not fully reverified.
Primary-agent trial review — 16 September 2026
Additional current-status correction.
The rezpegaldesleukin-newonset record was additionally compared with the 8 September 2026 registry update: 15 listed sites, 14 US recruiting and one Canadian not yet recruiting. Current age-cohort openings are not established by the registry. Removed the stale assertion that children cannot yet join and the unsupported claim that a shared C-peptide endpoint makes treatments directly comparable.